H.C. Wainwright Reiterates Buy Rating on MapLight Therapeutics (MPLT)
Tweet Send to a Friend
H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $45.00 price target on MapLight Therapeutics (NASDAQ: MPLT).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


